普伐他汀对慢性心力衰竭患者心功能及血清C反应蛋白的影响

目的 探讨普伐他汀对慢性心力衰竭(CHF)患者心功能及血清C反应蛋白(CRP)水平的影响.方法 90例CHF患者随机分为他汀组(45例)和对照组(45例).他汀组在常规治疗基础上加用普伐他汀40mg/d;对照组常规治疗.两组患者治疗前、治疗后3个月检测血清CRP及行超声心动图检查测定左心室射血分数(LVEF).结果 两组患者治疗3个月后与治疗前比较,TC、血清CRP水平均有不同程度降低,且他汀组血清CRP水平较对照组明显下降(15.47±9.83)mg/L,(20.31±7.15)mg/L,P<0.05],LVEF较对照组明显上升(45.70±7.01)%,(38.34±5.31)%,P<0.05];血清CRP水平与LVEF呈负相关(r=-0.495,P<0.05).结论 普伐他汀能改善CHF患者的预后;血清CRP水平可作为治疗CHF的一个灵敏观察指标.

Effect of pravastatin on cardiac function and serum C-reactive protein levels in patients with chronic heart failure

Objective To study the effect of pravastatin on cardiac function and serum C-reactive protein (CRP) levels in patients with chronic heart failure (CHF). Methods 90 patients with CHF were randomly divided into pravastatin group (n=45) and control group (n=45). Pravastatin 40mg/d was administered in addition to the routine treatment for pravastatin group; the control group was received the routine treatment. All patients with CHF were examined serum CRP levels, LVEF at pretherapy and 3 months by ultrasonic cardiogram. Results At 3 months C-reactive protein levels were degraded in varying degree, and the serum CRP levels in pravastatin group was significantly lower than that in control group (15.47±9.83)mg/L vs (20.31±7.15)mg/L](P<0.05), LVEF was significantly higher than that in control group(45.70±7.01)% vs (38.34±5.31)%](P<0.05); the serum CRP levels was positively related to LVEF (r=-0.495,P<0.05). Conclusion Pravastatin may improve the prognosis in patients with CHF, and can be used as a sensitive index for pravastatin treatment of CHF.